Research programme: glycogen phosphorylase inhibitors - sanofi-aventis

Drug Profile

Research programme: glycogen phosphorylase inhibitors - sanofi-aventis

Alternative Names: AVE 2865; AVE 9423; Glycogen phosphorylase inhibitors research programme - sanofi-aventis

Latest Information Update: 18 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Class
  • Mechanism of Action Glycogen phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 31 Dec 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in Europe (unspecified route)
  • 26 May 2006 In the latest pipeline of February 24, 2006, sanofi-aventis showed only AVE 9423 in preclinical development
  • 26 May 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top